Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SU011248; Gemcitabine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SU011248; Gemcitabine | DRUG | Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity |
Inclusion Criteria: * Patients with diagnosis of a solid cancer which is not responsive to standard therapy or for which no standard therapy exists * Patient has good performance status (ECOG 0 or 1) Exclusion Criteria: * Prior treatment with either gemcitabine or SU011248 * Hypertension that can...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
SU011248 is an investigational small molecule being studied for the treatment of solid tumors. It is being evaluated in combination with gemcitabine in patients with advanced solid tumors. The drug is in Phase 1 clinical development and is not yet approved for any use.
SU011248 is being developed by Pfizer, Inc., a company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for the treatment of solid tumors.
SU011248 is in Phase 1 clinical development. It is an investigational drug being studied for the treatment of solid tumors and has not been approved by regulatory authorities. The drug is being evaluated in combination with gemcitabine.
SU011248 has been studied in one clinical trial, identified as NCT00615446. This Phase 1 trial, titled "A Study To Find The Best Doses Of SU011248 And Gemcitabine When Given Together To Patients With Advanced Solid Tumors," has been completed. The trial enrolled 44 participants in the United States.
No, SU011248 and gemcitabine are different drugs. SU011248 is an investigational small molecule being developed by Pfizer, while gemcitabine is a separate chemotherapy agent. In the clinical trial NCT00615446, the two drugs are being studied in combination for the treatment of advanced solid tumors.